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Abstract
Background—Barrett’s esophagus (BE) is often asymptomatic and only a small portion of BE 
patients are currently diagnosed and under surveillance. Therefore, it is important to develop risk 
prediction models to identify high-risk individuals with BE. Familial aggregation of BE and 
esophageal adenocarcinoma (EAC), and the increased risk of EAC for individuals with a family 
history, raise the necessity of including genetic factors in the prediction model. Methods to 
determine risk prediction models using both risk covariates and ascertained family data are not 
well-developed.
Methods—We developed a Barrett’s Esophagus Translational Research Network (BETRNet) risk 
prediction model from 787 singly ascertained BE pedigrees and 92 multiplex BE pedigrees, fitting 
a multivariate logistic model that incorporates family history and clinical risk factors. The eight 
risk factors age, sex, education level, parental status, smoking, heartburn frequency, regurgitation 
frequency, and use of acid suppressant, were included in the model. The prediction accuracy was 
evaluated on the training dataset and an independent validation dataset of 643 multiplex BE 
pedigrees.
Results—Our results indicate family information helps to predict BE risk, and predicting in 
families improves both prediction calibration and discrimination accuracy.
Conclusions—Our model can predict BE risk for anyone with family members known to have, 
or not have, had BE. It can predict risk for unrelated individuals without knowing any relatives’ 
information.
Keywords
Barrett’s esophagus; Esophageal adenocarcinoma; Clinical predictors; Genetic factors; family
Introduction
During the past thirty years, the incidence of esophageal adenocarcinoma (EAC) has 
increased dramatically up to 7-fold in the United States (1,2). EAC is a lethal cancer with 5-
year survival rates lower than 20% (3). Barrett’s esophagus (BE) is the only known 
precursor for EAC, with BE patients having an 11- to 30-fold increased risk of developing 
EAC (4,5). Moreover, BE and EAC aggregate in some families (6). The population 
prevalence of BE is estimated to be between 1-3% (7,8), and the prevalence of BE in the 
family members of patients who had BE is estimated to be higher than in the general 
population (8%) (9). However, BE is often asymptomatic and, among older people, it may 
actually be associated with a decreased GERD symptom burden (10,11). It is estimated that 
only 5% of patients who have BE are currently diagnosed and under surveillance. The 
majority of EAC patients do not have an antecedent diagnosis of BE and are diagnosed in 
the late stages of the disease (12). To detect EAC early, it is necessary to first develop a risk 
prediction model that identifies high-risk individuals with BE.
To date, models that include clinical/environmental risk factors for predicting BE or EAC 
risk have been developed using unrelated case-control or cohort data (13-17). Although the 
rapidly increasing incidence of EAC in recent decades indicates the importance of 
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environmental factors in assessing the disease risk, familial aggregation of Barrett’s 
esophagus and esophageal adenocarcinoma, and the increased risk of EAC for individuals 
with a family history (6,9), raise the necessity of including familial factors in the prediction 
model. The heritability of polygenic liability to BE and EAC has been estimated to be 35% 
and 25%, respectively (18). In this study, we developed a Barrett’s Esophagus Translational 
Research Network (BETRNet) model that incorporates family members’ information in 
addition to clinical risk factors in predicting an individual’s absolute risk of BE.
Material and methods
Data
BE was rigorously defined as the presence of intestinal metaplasia in biopsies obtained from 
endoscopically-visible columnar mucosa in the tubular esophagus. Intestinal metaplasia on 
biopsies of the gastroesophageal junction or an irregular Z-line was not accepted as BE. We 
considered BE, EAC, and gastroesophageal junctional adenocarcinomas (JAC) to be part of 
the same trait, theorizing that at least a proportion of these cancers arose from BE. For 
assessing risk of BE in our prediction models we considered any individual with BE, EAC, 
or gastroesophageal junctional adenocarcinoma to be affected. Individuals were considered 
unaffected only if they had upper endoscopy that excluded Barrett’s esophagus. To ascertain 
the exposure variables, we used a standardized questionnaire based on the validated MAYO 
GERD questionnaire (19). This modified questionnaire has previously been used in studies 
of familial aggregation (20).
Through the Barrett’s Esophagus Translational Research Network (BETRNet), we collected 
two independent sets of Barrett’s esophagus pedigree data, which are respectively used as 
training and validation data. The training set comprises 787 singly ascertained and 92 
multiplex pedigrees, each of which includes two or more persons, at least one of which is 
affected with BE or EAC. Single ascertainment assumes that a pedigree enters the sample 
analyzed because of only a single proband. Our methodology for collecting this initial set of 
pedigrees has been previously reported (6,20,21). These pedigrees were used to estimate the 
parameters of the prediction model (coefficients of covariates, genotypic susceptibilities and 
the allele frequency at a trait locus). The independent validation dataset was collected 
separately but used the same trait definitions and comprised 643 multiplex familial BE 
pedigrees. A summary of the characteristics of the members of the training and validation 
datasets is shown in Table 1.
The prediction model
Using a pedigree likelihood based on a multivariate logistic model (MLM) that includes 
segregation at a major trait locus (22), we assessed the predictive utility of genetic factors, 
demographic factors (age, sex, body mass index (BMI), education level, parental status), 
environmental factors (smoking, alcohol consumption, use of acid suppressant medications, 
gastroesophageal reflux symptoms such as GERD and heartburn), and affection status 
among family members. The prediction model was obtained from a generalized and 
modified version of the SEGREG program in the S.A.G.E. package (23). In SEGREG, 
although there is no restriction on the size of the family, the family is assumed to be non-
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inbred and to contain no children of consanguineous spouse pairs. We considered all the 
predicting variables that were reported to be risk factors of BE or EAC (13-17), and found 
13 variables available in our data.
Values of the predictor variables for most of the unaffected individuals were missing in both 
the training and validation datasets (Supplementary Table S1). Nevertheless, we were able to 
impute age (for the missing 40%) using the family structure according to the method of 
Schnell et al (24). Moreover, observing that the sum of known date of birth (DOB) and age 
at examination are mostly between 1999 and 2010, we could to a good approximation 
assume that the time of diagnosis (DOB + age at examination) is equal for all members in a 
family, and hence impute age on 98.5% of the individuals (Supplementary Methods, 
Supplementary Figures S1 - S2). The training dataset of 787 pedigrees that we used initially 
to estimate the parameters for the prediction model has missing values on the predictor 
variables for most of the unaffected individuals (94% missing, Supplementary Table S1). 
Because the missingness depends on the affection status, not on the predictor variable 
values, it should not influence the estimation of regression coefficients on the covariates; but 
it will influence the estimation of the baseline risk, which is related to the genetic parameters 
(the allele frequencies at an assumed trait locus and the genotypic penetrances). However, 
because the ascertainment of the BE pedigrees would also influence estimation of the 
genetic parameters, we estimated the covariate and genetic parameters in the MLM model in 
two separate steps (figure 1).
Step 1. Determine and estimate the covariate regression coefficients. In this step, we fitted 
multivariate logistic models without adjusting for ascertainment using the training data of 
787 pedigrees. We initially included all the thirteen prediction variables (ln(age), sex, 
education level, parental status, years of smoking, smoking packs per day, use of alcohol, 
heartburn frequency, age of onset of heartburn, regurgitation frequency, age of onset of 
regurgitation, BMI, and use of acid suppressant) as covariates of a single baseline 
susceptibility in the MLM model. The clinical predictors were coded to make the variables 
jointly linear on the susceptibility scale (logit scale) (Supplementary Methods, 
Supplementary Figures S3, S4). We then stepwise removed covariates on the basis of 
likelihood ratio tests (LRT) and Akaike’s information criterion (AIC). This analysis is 
identical to multivariable logistic regression. We also evaluated the covariates of 
susceptibility by fitting MLM models with two genetic susceptibilities of a latent two-allele 
locus (Supplementary Table S2). This analysis, in which the penetrance of the heterozygote 
could equal that of either homozygote, indicated incomplete dominance of the disease-
susceptibility allele. Eight covariates, ln(age), sex, education level, parental status, years of 
smoking, heartburn frequency, regurgitation frequency, and use of acid suppressant, were 
finally determined as the variables to use as covariates in the prediction model 
(Supplementary Table S3). Their regression coefficients estimated in the MLM model that 
assumed a mixture of two (latent) genetic susceptibilities determined by a dominant one-
locus model were used in the prediction.
Step 2. Estimate the genetic parameters. In order to estimate the genetic parameters of the 
MLM model, which are the genotypic susceptibilities on the logit scale and the population 
allele frequency at the trait locus, we refitted by maximum likelihood the two-allele model, 
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but now adjusting the likelihood for ascertainment. In doing this the estimates of the 8 
covariates were fixed at the estimates from the first step The 787 BE pedigrees in the 
training dataset were taken to be singly ascertained, so in estimating the genetic parameters 
we adjusted for single ascertainment in the likelihood function by conditioning the 
likelihood function on the phenotype of the proband. Once again the result indicated 
incomplete dominance of a disease-susceptibility allele.
The additional multiplex 92 BE pedigrees, which were collected later, were not singly 
ascertained. We combined them with the 787 singly ascertained pedigrees, and also 
estimated the genetic parameters using these 879 pedigrees. Because the 879 pedigrees were 
not all singly ascertained, we both used an adjustment for single ascertainment and 
additionally added a prevalence constraint on the model when maximizing the likelihood 
function (25), the population prevalence being constrained to that estimated from the 787 
pedigrees.
With the estimated parameters for the prediction models, the probability that a random 
family member i will have BE (by a particular age and at defined covariate values, omitted 
below for clarity), given the family information available, is then obtained from the pedigree 
likelihoods according to Bayes’ theorem:
(1)
where LA=L(i is affected, other family members’ information) is the pedigree likelihood 
with individual i assumed to be affected and LU=L(i is unaffected, other family members’ 
information) is the pedigree likelihood with individual i assumed to be unaffected. Both 
pedigree likelihoods can be outputs of SEGREG.
Evaluating the prediction accuracy of the model
Two assessments were used to evaluate the accuracy of the prediction model. One used the 
calibration criterion, which measures how well the average predicted probabilities agree 
with the proportion of individuals who actually developed disease. The other used the 
discrimination criterion, which measures how well the model can separate cases (affected) 
from controls (unaffected). The calibration assessment we used is the ratio of the observed 
count to the expected count of BE subjects, O/E (26,27). The expected count is the sum of 
the predicted probabilities of being affected with BE over all individuals in the sample, and 
the observed count is the actual number of affected individuals. A 95% confidence interval 
for this ratio is between a lower limit of (O/E)exp(−1.96×O−1/2) and an upper limit of (O/
E)exp(1.96×O−1/2) (26,27). A P-value for departure from goodness-of-fit can be obtained 
from the χ2 distributed statistic (O-E)2/E with one degree of freedom (26,27). The 
discrimination assessment we used is the c statistic, which is the area under the receiver 
operating characteristic (ROC) curve (AUC). The c statistic is a function of sensitivity (true 
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positive rate) and specificity (true negative rate); it measures the probability that predicting 
the outcome is better than chance (50%).
With the estimated prediction model, we can predict the absolute risk for an individual in a 
randomly sampled pedigree using formula (1), by calculating two unconditional pedigree 
likelihoods while fixing the parameter estimates in the MLM model. The prediction 
accuracy of the prediction model was evaluated in the independent validation dataset of 643 
BE pedigrees, as well as in the 787 pedigrees of the training dataset. However, neither 
dataset was randomly sampled from the population: the data on the 787 BE pedigrees were 
singly ascertained through a proband, the independent data on the 643 BE pedigrees were 
multiplex pedigrees.
In order to predict the risk for individuals in singly ascertained pedigrees, we need to 
calculate the pedigree likelihoods conditioned on the appropriate subset C, which includes 
the probands (23). The risk for such an individual is:
(2)
where LAC and LUC are the two conditional pedigree likelihoods output by SEGREG on 
adjusting for single ascertainment.
In SEGREG,
(3)
and
(4)
where LA and LU are as given in formula (1) and LC is the likelihood function for the 
proband. C is the subset of pedigree members to be conditioned on, which includes only the 
probands (singly ascertained pedigrees have one proband per pedigree). LC is taken to be the 
pedigree likelihood L computed as though all individuals not in C are missing (23).
(1) For a non-proband in a singly ascertained pedigrees, according to formulae (2) - 
(4), the probability of being affected given his/her family members’ information 
and the proband’s status is , which 
means his/her risk equals the risk for an individual in a randomly sampled 
pedigree. This equality is intuitive, because for a non-proband in a singly 
ascertained pedigree, the probability of being affected pic = prob(individual i is 
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affected|other family members’ information, and the proband’ s information and 
affected status), and because the proband is one of the “other family members”, 
pic = prob(individual i is affected|other family members’ information) = pi. This 
equality also indicates that single ascertainment can be automatically adjusted 
by predicting in a family.
(2) For a proband in a singly ascertained pedigree, the probability of being affected 
is (see Supplementary Methods)
(5)
This shows that because the proband’s affection status in a singly ascertained pedigree is 
already known, the risk of a proband being affected is either 1 or 0 depending on affection 
status.
In evaluating the prediction model using our ascertained pedigrees, we used formula (1) or 
(2) to predict the BE risk for non-probands (they produce exactly the same risk), and used 
formula (5) to predict the risk for probands. For any individual from a random family or for 
an unrelated individual in the population, we can predict his/her BE risk by formula (1). The 
prediction accuracy for all individuals (probands and non-probands) and for the non-
probands alone were respectively evaluated.
Estimating the variance due to genetic factors and the variance due to environmental, 
demographic and clinical factors
In order to study how much the prediction is improved by using family information, we 
estimated the variance due to genetic factors and the variance due to other factors using the 
training dataset that the model was estimated from, because it had many more non-probands 
than did the validation dataset. We predicted the risk for individual i in a family (denoted by 
R(Gi,xi)), and estimated the predicted risk for any individual i assuming all individuals are 
unrelated, which means that everyone has the same genotypic frequencies , and has the 
corresponding risk R( ,xi). We also estimated the risk in families but assuming that every 
individual has the same covariate value  (  = E(x)), and thus estimated the corresponding 
risk R(Gi, ). Whether on the logit scale or on the probability scale, the genetic factors 
(genotypic frequencies G) and the environmental factors (covariates x) are not linear in the 
risk, and therefore among the non-probands (as well among all individuals), mean(R(Gi,xi)) 
≠ mean(R( ,xi)) ≠ mean(R(Gi, )). In order to roughly estimate the variance explained by 
the genetic and environmental factors, we made the three means equal in the following way. 
In estimating R( ,xi), we found the allele frequency (q = 0.096) that made mean(R( ,xi)) = 
mean(R(Gi,xi)) (where mean(R(Gi,xi)) = 0.113); Similarly, in estimating R(Gi, ), we found 
the value k (k = −0.433) that made the mean covariate value  ( =E(x)+k×SD(x)×sign(βx)) 
such that (R(Gi, )) = mean(R(Gi,xi)) = 0.113, where sign(βx) is the sign of the estimated 
regression on covariate x.
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Results
The estimated parameters in the prediction model
Using the 787 singly ascertained pedigrees, we estimated the coefficients of the predictor 
covariates without adjusting for ascertainment in a multivariable logistic model that assumed 
a mixture of two (latent) genetic susceptibilities determined by a dominant one-locus model. 
The estimates of the regression coefficients (Table 2) should be approximately unbiased 
provided only that the linear logistic model is appropriate for the fixed effects (28).
The genetic parameters (genotypic susceptibilities and allele frequency of the trait locus) 
were then estimated by maximum likelihood under a dominant model while adjusting the 
likelihood for ascertainment. In estimating the genetic parameters, the 8 covariates were 
fixed at the estimates in Table 2. The estimate of the genetic parameters using the 787 singly 
ascertained pedigrees (model 1) and the one with additional 92 pedigrees (model 2) are 
listed in Table 3; on the penetrance scale the estimates from the two datasets are close to 
each other.
Predicting BE risk from the prediction model
As an example, we show in Table 4 the probability that a family member will have BE by 
age 50 or 70 according to the affection status of one or two older siblings. As we can see, for 
a 50 year old male, if he has one sister with BE and one sister without BE (the last row), his 
probability of being affected is 13.8% (by prediction model 1); if he has both sisters 
affected, his probability of being affected increases to 32.9%; and if he has two affected 
brothers, his probability of being affected is 26.6%.
Prediction accuracy
The accuracy of the prediction model that was fitted from the training dataset of 787 singly 
ascertained pedigrees (model 1) was evaluated separately on both the training dataset itself, 
and the independent validation dataset of 643 pedigrees. We evaluated this model because 
this model is fitted by the 787 singly ascertained pedigrees and theoretically such single 
ascertainment has been accurately adjusted for in this model. Moreover, the ascertainment 
adjustment of model 2 was based on the prevalence from model 1, and the estimates and the 
predictions of the two models are very close, so we evaluated the fundamental model 1. In 
these two datasets, the clinical variables used in the prediction model were largely missing, 
especially on the unaffected individuals. In the training dataset, there were 689 pedigrees 
with 1170 individuals who were informative for all the covariates (Table 1), and in the 
validation dataset, only 248 pedigrees with 420 individuals were informative for all the 8 
covariates. These are the individuals who were used to predict the risk of Barrett’s 
esophagus.
Because the datasets were not randomly ascertained, predicted BE risks for the probands are 
known to be either 0 or 1 (formula 5), so prediction for non-probands is more meaningful to 
evaluate the prediction performance. As we can see in Table 5, prediction using relatives’ 
information (predicting in a pedigree) has better calibration accuracy O/E than prediction 
without relatives’ information (prediction assuming the individuals are unrelated, i.e., each 
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individual is assumed to be in a one-individual pedigree). In the training dataset, the 
prediction O/E for non-probands is 0.943 (95% CI: 0.722 to 1.231) when predicting with 
relatives’ information, but is 1.666 (95% CI: 1.276 to 2.176) when predicting without 
relatives’ information, indicating that predicting without using relatives’ information 
significantly underestimates the BE risk (P = 1.48×10−4). In the validation dataset, although 
O/E for prediction with relatives’ information is 1.378 (95% CI: 0.931 to 2.039), the 
overestimate of BE risk is not significant (P = 0.108); while O/E for prediction without 
relatives’ information is 2.564 (95% CI: 1.732 to 3.794), suggesting significant 
underestimation of BE risk when predicting without family information (P = 1.05×10−6). 
Prediction with relatives’ information also had better discrimination accuracy, AUC, than 
prediction without relatives’ information in the training dataset: for non-probands, AUC was 
0.753 vs. 0.741 respectively for prediction with and without relatives’ information. However, 
in the validation dataset, the change in AUC between prediction with and without family 
information was very small (0.803 vs. 0.806). Our results indicate that, on average, 
prediction in families has better prediction accuracy than prediction without relatives’ 
information; family information improves the prediction accuracy.
Variances due to genetic factors and to environmental/demographic/clinical factors
After making mean (R(Gi,xi)) = mean (R( ,xi)) = mean (R(Gi, )), the sum of squares (ss) 
due to genetic factors, the other factors, and the total ss were respectively 
; ; 
. Thus, because ssGi/(ssGi + ssxi = 11.327 > 
9.775 = sstotal, there appeared to be no interaction between Gi and xi. Estimating ssGi/(ssGi + 
ssxi) = 21.9%, the genetic factors contributed about 22% and the other factors about 78% of 
the total variance in the 787 singly ascertained pedigrees.
Discussion
In this study, we developed a BETRNet model to predict absolute risk of Barrett’s esophagus 
in families by incorporating into the model both clinical and genetic factors. Based on the 
values of multiple clinical variables for family members, our model can predict BE risk for 
anyone with family members known to have had, or not have had, BE. It can also predict for 
unrelated individuals without any relatives’ information. Our results indicate that the family 
information helps to predict BE risk, and predicting in families improves both the prediction 
calibration and the discrimination accuracy. Our prediction model will lead to effective 
identification of high risk individuals for BE screening and surveillance, consequently 
allowing intervention at an early stage leading to a reduction in mortality from esophageal 
adenocarcinoma.
Compared with other BE and EAC prediction models (13-17), our prediction model has the 
advantage of incorporating information on relatives. However, if no information on relatives 
is available, our prediction model can still predict for such “unrelated” individuals in the 
same way that the other prediction models do. Moreover, if BE causal genes are discovered, 
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it will easily allow incorporation of such causal genes into the model. In addition, the model 
can adjust for single ascertainment for predicting in a family.
Our definition of “affected” status has included BE and its associated cancers because they 
are epidemiologically similar and there is strong evidence that nearly all EACs and a 
substantial proportion of junctional cancers arise in Barrett’s epithelium (4,5,29). Some of 
the cancers included in this prediction model may not have arisen in BE. However, because 
the prevalence of BE is much higher than that of cancer, it is unlikely that this 
misclassification will affect the prediction model. It is important to note that this model 
should be used only for families in which BE is rigorously defined by confirming the 
presence of intestinal metaplasia in biopsies obtained from visible columnar mucosa in the 
tubular esophagus. The prediction model should not be used in families where the diagnosis 
of BE has not been confirmed in family members.
Clinical data were collected on both affected and unaffected family members using a FBE 
questionnaire (20) based on the Mayo GERQ (19). However, because the major goal in 
collecting the pedigrees used in this study was to discover susceptibility genes for BE and 
EAC, family members affected with BE, EAC, or gastroesophageal junctional 
adenocarcinomas were much more likely to participate than unaffected family members. The 
large proportion of missing data on the covariates among the unaffected individuals in the 
training dataset could result in biased estimates of the genotypic susceptibilities, or of the 
allele frequencies for the genetic trait locus, but any such bias could not be identified by our 
validation data, which had a similar missing-value problem. In addition, our result showed 
that in the training data the calibration assessment (O/E) is close to 1, while in the validation 
dataset our prediction underestimated BE risk, which may indicate the difference in 
ascertainment between the training and validation datasets. However, the possible bias 
should not be serious because the estimated population prevalence of Barrett’s esophagus 
from our prediction model is 3.0%, close to the reported population prevalence (7). 
Moreover, the missing data resulted in loss of family information (Supplementary Table S4); 
71% of the pedigrees in the training set had only one informative individual, which could be 
the reason the prediction with relatives’ information did not improve much on discrimination 
accuracy (AUC) compared with prediction without such information. Despite the missing 
data, our study shows that our model, which included family information, was able to 
predict risk of BE.
Note that although we modeled the familial effect as a latent variable in the form of a 
diallelic susceptibility locus, this does not imply that this is the true genetic model; the true 
underlying model is undoubtedly more complex, in terms of both genetics and the 
environment. What we have demonstrated in this paper is the importance of including this 
familial effect into the prediction model. As shown in the example scenarios in Table 4, for a 
male at age 50 with an unaffected brother, his risk is 3.2%; but if he has one affected brother, 
his risk is almost tripled (9.1%); furthermore, if he has two affected brothers, his risk is 
further tripled (26.6%). These increases are attributable to the genetically modeled familial 
effect. What may appear to be a peculiarity in Table 4 is that in some instances the 
probability of being affected is seen to be higher at age 50 than at age 70. This arises 
because the sibs are assumed to be about the same age as the family member. Consider, for 
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example, a male at age 50 with two affected brothers, for whom the predicted risk is 26.6%; 
whereas (in the same line of the table) at age 70 his risk is only 20.1%. In the former case 
we know that the two brothers were already affected by ages 52 and 54, whereas in the latter 
case they may have become affected when up to 20 years older, implying the possibility of a 
lower genetic predisposition in the family.
In a future study, as more BE pedigrees and more informative individuals in pedigrees are 
prospectively and rigorously collected, we could improve our prediction model with updated 
data, and further validate it against external populations. Extensive simulation studies could 
help find more appropriate strategies to deal with complex ascertainments and missing data, 
to improve the estimation of clinical and genetic parameters in the prediction model. 
Simulation studies could also help determine the value of risk prediction for different genetic 
models, for example, if the disease is transmitted largely recessively. Furthermore, a web-
based application (30) has been developed to allow risk calculations with subsequent 
endoscopy data, so that the model could be monitored over time to improve its accuracy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Impact
Our prediction model will shed light on effectively identifying high risk individuals for 
BE screening and surveillance, consequently allowing intervention at an early stage and 
reducing mortality from esophageal adenocarcinoma.
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Figure 1. 
Flowchart of developing the prediction model
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Table 1
Demographic Characteristics of the pedigree members used for prediction and validation, with numbers of 
individuals (%)
Training Validation
689 pedigreesa 743 pedigreesb 248 pedigreesc
Affected 716 (61.2) 773 (61.9) 237 (56.4)
Male 576 (80.4) 620 (80.2) 198 (83.5)
Female 140 (19.6) 153 (19.8) 39 (16.5)
Subcategories of diagnosis:
BE 402 (56.1) 434 (56.1) 97 (40.9)
SSBE 103 (14.4) 192 (24.8) 62 (26.2)
ECA 177 (24.7) 34 (4.4) 68 (28.7)
JCA 34 ( 4.7) 113 (14.6) 10 ( 4.2)
Education level:
< High school 69( 9.6) 73( 9.8) 16( 6.8)
high school 353(49.3) 389(52.4) 117(49.4)
college and beyond 294(41.1) 311(41.9) 104(43.9)
Heartburn frequency:
None 172(24.0) 172(23.1) 63(26.6)
≤ once a week 319(44.6) 349(47.0) 105(44.3)
several times a week or everyday 225(31.4) 252(33.9) 69(29.1)
Regurgitation frequency:
None 195(27.2) 196(26.4) 75(31.6)
≤ once a month 295(41.2) 326(43.9) 99(41.8)
weekly or more 226(31.6) 251(33.8) 63(26.6)
Unaffected 454 (38.8) 476 (38.1) 183 (43.6)
Male 197 (43.4) 206 (43.3) 71 (50.4)
Female 257 (56.6) 270 (56.7) 112 (48.7)
Education level:
< High school 21( 4.6) 21( 4.4) 5( 2.7)
high school 168(37.0) 177(37.2) 57(31.1)
college and beyond 265(58.4) 278(58.4) 121(66.1)
Heartburn frequency:
None 126(27.8) 128(26.9) 68(37.2)
≤ once a week 214(47.1) 224(47.1) 85(46.4)
several times a week or everyday 114(25.1) 124(26.1) 30(16.4)
Regurgitation frequency:
None 183(40.3) 185(38.9) 81(44.3)
≤ once a month 200(44.1) 206(43.3) 67(36.6)
weekly or more 71(15.6) 85(17.9) 35(19.1)
Total 1170 1249 420
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Training Validation
689 pedigreesa 743 pedigreesb 248 pedigreesc
Male 773 (66.1) 826 (66.1) 269 (64.0)
Female 397 (33.9) 423 (33.9) 151 (36.0)
Education level:
< High school 90( 7.7) 94( 7.5) 21( 5.0)
high school 521(44.5) 566(45.3) 174(41.4)
college and beyond 559(47.8) 589(47.2) 225(53.6)
Heartburn frequency:
None 298(25.5) 300(24.0) 131(31.2)
≤ once a week 533(45.6) 573(45.9) 190(45.2)
several times a week or everyday 339(29.0) 376(30.1) 99(23.6)
Regurgitation frequency:
None 378(32.3) 381(30.5) 156(37.1)
≤ once a month 495(42.3) 532(42.6) 166(39.5)
weekly or more 297(25.4) 336(26.9) 98(23.3)
aA subset of 787 singly ascertained pedigrees with members who are informative on all the clinical variables
bA subset of 879 pedigrees (787pedigrees+92multiplex pedigrees) with members who are informative on all the clinical variables
cA subset of 643 validation pedigrees with members who are informative on all the clinical variables
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Table 2
Estimated effects of covariates using the data on 787 singly ascertained pedigrees
Covariates Estimate S.E. OR 95% CI of OR
Sex −2.101 0.257 0.122 (0.074, 0.202)
Parent 1.015 0.216 2.759 (1.807, 4.214)
Log(age) 3.057 0.416 21.264 (9.409, 48.055)
Years of Smoking 0.021 0.0007 1.021 (1.020, 1.023)
HeartburnFreq −0.245 0.156 0.783 (0.577, 1.063)
RegurgFreq 0.879 0.167 2.408 (1.736, 3.341)
Education −0.418 0.166 0.658 (0.476, 0.912)
Use of acid suppressant 1.506 0.304 4.509 (2.485, 8.181)
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Table 3
Estimated population susceptibility parameters and allele frequency from 787 BE pedigrees and 879 BE 
pedigrees, on adjusting for ascertainment
Model 1a Model 2b
Parameters Estimate S.E. OR 95% CI
of OR Estimate S.E. OR
95% CI
of OR
Susceptibilityc
AA, AB
−12.961 0.628 81.70 (13.73, 486.17) −12.715 0.871 90.56 (5.81, 1410.79)
Susceptibility
BBc
−17.075 0.420 1 −16.854 0.363 1
Frequency of A 0.027 0.016 0.021 0.142
Prevalence
(non-parent at
age 50)
0.030 0.030
Note: OR: Odds Ratio. S.E.: Standard error. CI: Confidence Interval.
aAdjusting for single ascertainment using 787 pedigrees, finding prevalence = 3.0%
b
Estimated with 879 pedigrees by adjusting for single ascertainment and using prevalence constraint from model 1 (3.0%)
c
The estimates are on the logistic scale
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Table 4
Predicted probability (%) of a family member having BE by (Model 1, Model 2) using the parameter values in 
tables 2 and 3, the values of covariates other than sex, parent and log(age) are at the mean values shown in 
Supplementary Table S3. Parents of the family members are assumed to be unaffected with BE
1st sib
4 years older than
the Family Member
2nd sib
2 years older than the
Family Member
Sex, age of Family Member
Male, 50 Female, 50 Male, 70 Female, 70
Male without BE N/A
3.2 0.5 7.7 1.1
3.7 0.5 9.2 1.3
Female without BE N/A
3.4 0.5 7.8 1.2
3.9 0.6 9.3 1.3
Male with BE N/A
9.1 2.1 10.3 2.4
7.6 1.8 10.7 2.1
Female with BE N/A
14.6 3.7 15.8 5.0
12.5 3.3 14.5 4.2
Male with BE Male with BE
26.6 7.1 20.1 7.1
23.4 6.8 16.2 5.1
Male with BE Male without BE
7.2 1.6 9.1 1.8
6.2 1.3 10.1 1.7
Female with BE Female with BE
32.9 8.9 41.0 17.1
34.3 10.3 38.9 17.5
Female with BE Female without BE
13.8 3.5 14.4 4.3
11.7 3.1 13.3 3.5
NOTE: N/A: no affection status known for a second sibling
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